Advancing biotechnology through cutting-edge research, innovation, and scientific collaboration.

Platform

Resources

About Us FAQ Contact Privacy Policy Terms & Conditions Cookie Policy

News & Comments

A curated stream of biotech news paired with commentary and perspective on important events shaping the sector. Designed to help readers understand not just what happened, but why it matters.

574 Articles

News & Comments

View:

Showing 1 to 12 of 574 articles in News & Comments

News & Comments

Sentynl Therapeutics Inc Announces FDA Approval of ZYCUBO® for Menkes Disease in Pediatric Patients

Sentynl Therapeutics JANUARY 13, 2026, Sentynl Therapeutics – a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited (“Zydus Group”), announced that the U.S. FDA has approv...

Prohost Biotech

Jan 13, 2026

News & Comments

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Harmony Biosciences Epilepsy News and the Treatment of Dravet Syndrome Harmony Biosciences Holdings, Inc. (HRMY), announced that it will highlight new open-label extension data from the company’s in...

Prohost Biotech

Dec 3, 2025

News & Comments

Eli Lilly Lowers the Price of Zepbound® (tirzepatide) Single-Dose Vials

Lilly in the NEWS INDIANAPOLIS, December 1, 2025, Eli Lilly and Company (LLY) today announced Zepbound® (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the compan...

Prohost Biotech

Dec 1, 2025

News & Comments

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs, Including Parkinson's Disease

Aspen Neuroscience Aspen Neuroscience, Inc. - a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 million Series C financing round. Thi...

Prohost Biotech

Nov 21, 2025

News & Comments

Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

The Great Story from Regerneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) announced updated data for the Company’s investigational gene therapy DB-OTO for profound genetic hearing loss du...

Prohost Biotech

Oct 14, 2025

News & Comments

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option and License Agreement to Advance Vectorized Antibodies for the treament of Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

VectorY Therapeutics in the NEWS September 18, 2025 – VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative dise...

Prohost Biotech

Sep 18, 2025

News & Comments

Helping Your Pets to be Healthy and Live Longer

Boehringer Ingelheim The following is not for investors but for people who love pets and want them to be healthy and live longer. Those who care about animals should know what’s going on in the highl...

Prohost Biotech

Aug 12, 2025

News & Comments

Praxis Precision Medicines Radiant Study with Vormatrigine

Praxis Precision Medicines in the NEWS On Aug. 04, 2025, the biopharmaceutical company Praxis Precision Medicines (PRAX), translating genetic insights into the development of therapies for central...

Prohost Biotech

Aug 5, 2025

11m

News & Comments

ARS Pharmaceuticals Announces FDA Approval of neffy® for Type I Allergic Reactions, Including Anaphylaxi in Pediatric Patients

ARS Pharmaceuticals SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE), ARS Pharmaceuticals (SPRY) announced that the U.S. FDA has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I...

Prohost Biotech

Mar 6, 2025

11m

News & Comments

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

Nuvig Therapeutics in the NEWS Nuvig Therapeutics - a privately held biotech company, developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced t...

Prohost Biotech

Dec 5, 2024

News & Comments

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics US FDA Approval On October 25, 2024, Iterum Therapeutics (ITRM) announced that the U.S. FDA has approved Iterum’s new drug application for ORLYNVAH™ (sulopenem, etzadroxil, and pro...

Prohost Biotech

Oct 29, 2024

News & Comments

The United States FDA Approved Astellas’ product VYLOY in Combination with Fluoropyrimidine and Platinum-Containing Chemotherapy for the First-Line Treatment of Adults with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Astellas Pharma Inc Announcement Tokyo, Oct. 18, 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) announced that the United States FDA has approved VYLOY (zolbetu...

Prohost Biotech

Oct 21, 2024

Showing 1 to 12 of 574 results

Prohost BiotechResearch Platform

Advancing biotechnology through cutting-edge research, innovation, and scientific collaboration.

Platform

Articles Categories Tags

Resources

About Us FAQ Contact Privacy Policy Terms & Conditions Cookie Policy